HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
Hokkaido University Hospital >
Peer-reviewed Journal Articles, etc >

Phase II Study of Gefitinib Readministration in Patients with Advanced Non-Small Cell Lung Cancer and Previous Response to Gefitinib

Files in This Item:
Onc79-5-6_423-429.pdf244.44 kBPDFView/Open
Please use this identifier to cite or link to this item:

Title: Phase II Study of Gefitinib Readministration in Patients with Advanced Non-Small Cell Lung Cancer and Previous Response to Gefitinib
Authors: Asahina, Hajime Browse this author →KAKEN DB
Oizumi, Satoshi Browse this author →KAKEN DB
Inoue, Akira Browse this author
Kinoshita, Ichiro Browse this author →KAKEN DB
Ishida, Takashi Browse this author
Fujita, Yuka Browse this author
Sukoh, Noriaki Browse this author
Harada, Masao Browse this author
Maemondo, Makoto Browse this author
Saijo, Yasuo Browse this author
Dosaka-Akita, Hirotoshi Browse this author →KAKEN DB
Isobe, Hiroshi Browse this author →KAKEN DB
Nukiwa, Toshihiro Browse this author
Nishimura, Masaharu Browse this author →KAKEN DB
Keywords: Epidermal growth factor receptor (EGFR)
Epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI)
Non-small cell lung cancer (NSCLC)
Issue Date: Apr-2011
Publisher: Karger
Journal Title: Oncology : International Journal for Cancer Research and Treatment
Volume: 79
Issue: 5-6
Start Page: 423
End Page: 429
Publisher DOI: 10.1159/000326488
PMID: 21474967
Abstract: Objective: Salvage treatment for acquired resistance to gefitinib has yet to be developed. We conducted the first prospective phase II study of gefitinib readministration in previous gefitinib responders. Methods: Gefitinib (250 mg/day) was readministered to patients with advanced/metastatic non-small cell lung cancer (NSCLC) who had achieved objective response to initial gefitinib and subsequently received cytotoxic chemotherapy after disease progression with initial gefitinib. The primary endpoint was the objective response rate with gefitinib readministration. Secondary endpoints were disease control rate, progression-free survival (PFS), overall survival (OS), quality of life ((QOL), and toxicity. Changes in lung cancer-related symptoms were evaluated using the seven-item lung cancer subscale of the questionnaire. Results: Sixteen patients were enrolled between February 2005 and January 2008. Most had received ≥ 3 regimens of chemotherapy. Response and disease-control rates for all patients were 0% and 44%. Median PFS and OS were 2.5 months and 14.7 months, respectively. Four of 7 patients with stable disease experienced a long duration (≥ 6 months) of disease control without severe toxicity. Symptom improvement was observed in 2 of 12 patients (17%) for whom QOL was evaluable. Conclusion: Gefitinib represents a useful therapeutic option for selected previous gefitinib responders.
Rights: Copyright © 2011 S. Karger AG, Basel
Type: article (author version)
Appears in Collections:北海道大学病院 (Hokkaido University Hospital) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

Submitter: 大泉 聡史

Export metadata:

OAI-PMH ( junii2 , jpcoar )


Feedback - Hokkaido University